An Epidemiological Analysis of 28 Vivax Malaria Cases in Gimpo-si, Korea, 2020
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Since 1993, vivax malaria has been recognized as a public health burden in Korea. Despite of pan-governmental malaria-control efforts and the dramatic reduction in the burden of this disease over the last 10 years, vivax malaria has not been well controlled and has remained continuously endemic. We focused interviewed and examined the charts of 28 confirmed vivax malaria patients given malarial therapy for whom daily records were kept from Gimpo-si, Gyeonggido of Korea. Various epidemiological characteristics of vivax malaria, including the incubation period, medication used, and recurrence, and an evaluation of the parasitic characteristics from the focused interviews of patients from this region are described here. Most of the participants indicated the 3 most common symptoms of malaria (headache, chills and fever). Of the 28 cases, 2 experienced a second attack and there were 17 and 11 cases with short- and long-term incubation periods, respectively, yielding a short-term to long-term ratio of 1.5. Based on the parasitemia stages, most of the participants were tested at 5 to 7 days (11 cases) and 7 to 15 days (11 cases) after initial wave of asexual parasites. In conclusion, public health authorities should consider developing management measures to decrease the time lag for diagnosis and drafting unified and robust guidelines for drug use for malaria and drawing up unified and robust guidelines on the use of medication for malaria. It also suggests that routine monitoring, surveillance, and precise medical surveys in high-risk vivax malaria endemic areas are pivotal to controlling this persistent public disease and finally eliminating it from Korea.
Abstract
Since 1993, vivax malaria has been recognized as a public health burden in Korea. Despite of pan-governmental malaria-control efforts and the dramatic reduction in the burden of this disease over the last 10 years, vivax malaria has not been well controlled and has remained continuously endemic. We focused interviewed and examined the charts of 28 confirmed vivax malaria patients given malarial therapy for whom daily records were kept from Gimpo-si, Gyeonggido of Korea. Various epidemiological characteristics of vivax malaria, including the incubation period, medication used, and recurrence, and an evaluation of the parasitic characteristics from the focused interviews of patients from this region are described here. Most of the participants indicated the 3 most common symptoms of malaria (headache, chills and fever). Of the 28 cases, 2 experienced a second attack and there were 17 and 11 cases with short- and long-term incubation periods, respectively, yielding a short-term to long-term ratio of 1.5. Based on the parasitemia stages, most of the participants were tested at 5 to 7 days (11 cases) and 7 to 15 days (11 cases) after initial wave of asexual parasites. In conclusion, public health authorities should consider developing management measures to decrease the time lag for diagnosis and drafting unified and robust guidelines for drug use for malaria and drawing up unified and robust guidelines on the use of medication for malaria. It also suggests that routine monitoring, surveillance, and precise medical surveys in high-risk vivax malaria endemic areas are pivotal to controlling this persistent public disease and finally eliminating it from Korea.
참고문헌 (23)
- "The history of malaria, an ancient disease"[URL]
- "World Malaria Report 2020"[URL]
- Adams JH, Mueller I, "The biology of Plasmodium vivax", Cold Spring Harb Perspect Med, 7, pp.a025585~ (2017)[DOI]
- 박영일, "Epidemiological Characteristics of Re-emerging Vivax Malaria in the Republic of Korea (1993-2017)", The Korean Journal of Parasitology, 56(6), pp.531~543 (2018), 대한기생충학ㆍ열대의학회
- "WHO country cooperation strategy 2019-2023: Republic of Korea"[URL]
- "Malaria Surveillance, Monitoring &Evaluation: A Reference Manual" (2018)[URL]
- "Global Technical Strategy for Malaria 2016-2030"[URL]
- "Infectious Diseases surveillance System"[URL]
- "Infectious Disease Portal"[URL]
- Lim CS, "Response to chloroquine of Plasmodium vivax among South Korea soldiers", Ann Trop Med Parasitol, 93, pp.565~568 (1999)
- Moon KT, "Recurrence rate of vivax malaria in the Republic of Korea", Trans R Soc Trop Med Hyg, 103, pp.1245~1249 (2009)[DOI]
- "Treatment of malaria: Guidelines for Clinicians" (2020)[URL]
- Park SY, "Increasing malaria parasite clearance time after chloroquine therapy, South Korea, 2000-2016", Emerg Infect Dis, 26, pp.1852~1855 (2020)[DOI]
- Nishiura H, "Estimate of short- and long-term incubation periods of Plasmodium vivax malaria in the Republic of Korea", Trans R Soc Trop Med Hyg, 101, pp.338~343 (2007)[DOI]
- DouglasA.BURKETT, "Late season commercial mosquito trap and host seeking activity evaluation against mosquitoes in a malarious area of the Republic of Korea", The Korean Journal of Parasitology, 40(1), pp.45~54 (2002), 대한기생충학ㆍ열대의학회
- Youn-Kyoung Goo, "The unique distribution of the Plasmodium vivax merozoite surface protein 1 in parasite isolates with short and long latent periods from the Republic of Korea", Malaria Journal, 14(1) (2015), Springer Science and Business Media LLC[DOI]
- Milner Jr. DA, "Malaria pathogenesis", Cold Spring Harb Perspect Med, 8, pp.a025569~ (2018)[DOI]
- Day KP, "The biology of Plasmodium falciparum transmission stages", Parasitology, 116(suppl), pp.95~109 (1998)[DOI]
- Eichner M, "Genesis, sequestration and survival of Plasmodium falciparum gametocytes: parameter estimates from fitting a model to malaria therapy data", Trans R Soc Trop Med Hyg, 95, pp.497~501 (2001)[DOI]
- Bousema T, "Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination", Clin Microbiol Rev, 24, pp.377~410 (2011)[DOI]
- McKenzie EF, "Gametocytemia and fever in human malaria infections", J Parasitol, 93, pp.627~663 (2007)[DOI]
- McKenzie EF, "Gametocytemia in Plasmodium vivax and Plasmodium falciparum infections", J Parasitol, 92, pp.1281~1285 (2006)[DOI]
- Fernando D, "Primaquine in vivax malaria: an update and review on management issues", Malar J, 10, pp.351~ (2011)[DOI]